Gamble Jacqueline, Stevenson Michael, McClean Elizabeth, Heaney Liam G
Centre for Infection and Immunity, Queen's University of Belfast, Northern Ireland, UK.
Am J Respir Crit Care Med. 2009 Nov 1;180(9):817-22. doi: 10.1164/rccm.200902-0166OC. Epub 2009 Jul 30.
With the advent of new and expensive therapies for severe refractory asthma, targeting the appropriate patients is important. An important issue is identifying nonadherence with current therapies. The extent of nonadherence in a population with difficult asthma has not been previously reported.
To examine the prevalence of nonadherence to corticosteroid medication in a population with difficult asthma referred to a Specialist Clinic and to examine the relationship of poor adherence to asthma outcome.
General practitioner prescription refill records for the previous 6 months for inhaled combination therapy and short-acting beta-agonists were compared with initial prescriptions and expressed as a percentage. Blood plasma prednisolone and cortisol assay levels were used to examine the utility of these measures in assessing adherence to oral prednisolone. Patient demographics, hospital admissions, lung function, oral prednisolone courses, and quality of life data were analyzed to indentify the variables associated with reduced medication adherence.
A total of 182 patients were assessed. Sixty-three patients (35%) filled 50% or fewer inhaled medication prescriptions; 88% admitted poor adherence with inhaled therapy after initial denial. Twenty-one percent of patients filled more than 100% of presciptions, and 45% of subjects filled between 51 and 100% of prescriptions. Twenty-three of 51 patients (45%) prescribed oral steroids were found to be nonadherent.
A significant proportion of patients with difficult-to-control asthma remained nonadherent to corticosteroid therapy. Objective surrogate and direct measures of adherence should be performed as part of a difficult asthma assessment and are important before prescibing expensive novel biological therapies.
随着用于重度难治性哮喘的新型昂贵疗法的出现,确定合适的患者至关重要。一个重要问题是识别对当前疗法的不依从情况。此前尚未报道过难治性哮喘人群中的不依从程度。
研究转诊至专科诊所的难治性哮喘人群中皮质类固醇药物的不依从患病率,并研究依从性差与哮喘结局之间的关系。
将前6个月吸入联合疗法和短效β受体激动剂的全科医生处方 refill 记录与初始处方进行比较,并以百分比表示。使用血浆泼尼松龙和皮质醇测定水平来检验这些措施在评估口服泼尼松龙依从性方面的效用。分析患者人口统计学、住院情况、肺功能、口服泼尼松龙疗程和生活质量数据,以确定与药物依从性降低相关的变量。
共评估了182例患者。63例患者(35%)吸入药物处方的填充率为50%或更低;88%的患者在最初否认后承认吸入疗法依从性差。21%的患者处方填充率超过100%,45%的受试者处方填充率在51%至100%之间。51例接受口服类固醇治疗的患者中有23例(45%)被发现不依从。
很大一部分难治性哮喘患者仍不依从皮质类固醇治疗。在难治性哮喘评估中应进行客观替代指标和直接的依从性测量,在开具昂贵的新型生物疗法之前这很重要。